YKP3089

Phase 2Small molecule

SSK Life Science, Inc.

YKP3089 is one of 53 small molecule programs targeting Photosensitive Epilepsy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Photosensitive EpilepsyActive, not recruiting

SeizureActive, not recruiting

Photosensitive EpilepsyPhase 2

Active, not recruiting

SeizurePhase 2

Active, not recruiting

Competition

Competitive Landscape

109 competitors in Seizure

#DrugCompanyPhaseTrials

Briviact

UCB

Phase 3

12 2

Afinitor

Novartis

Phase 3

1 3

Fintepla

IImmedica Pharma AB

Phase 3

3 4

E2007

Eisai

Phase 3

6 5

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 3

1 6

Epsom Salt

FFresenius Kabi Oncology Ltd.

Phase 3

1 7

Ativan

BBausch Health Americas, Inc.

Phase 3

1 8

SPM 929

UCB

Phase 3

3 9

Valproate Sodium

Sanofi

Phase 3

1 10

RWJ-333369

SSK Life Science, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Seizure3 trials

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Completed·SSK Life Science, Inc.·Phase 2·NCT01866111·437 enrolled

Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

Completed·SSK Life Science, Inc.·Phase 3·NCT02535091·1,345 enrolled

Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures

Completed·SSK Life Science, Inc.·Phase 2·NCT01397968·222 enrolled

Photosensitive Epilepsy1 trial

Efficacy of YKP3089 in Patients With Photosensitive Epilepsy

Completed·SSK Life Science, Inc.·Phase 2·NCT00616148·11 enrolled

ESS1 trial

Cenobamate Expanded Access Program (EAP)

Approved for marketing·SSK Life Science, Inc.··NCT04513860

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for YKP3089. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — YKP3089 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for YKP3089. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — SK Life Science, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSK Life Science, Inc.

YKP3089

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Seizure3 trials

Photosensitive Epilepsy1 trial

ESS1 trial

References

Drug Info

Quick Facts

Related News